Political pressure on examiners is no way to reform India's patent system
The battle over the Indian patent sought by Gilead Sciences for its Hepatitis C drug Sofosbuvir (branded Sovaldi) seemingly came to a conclusion last week when the country's patent office reversed course to grant the US drug maker protection for…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now